9 results on '"Aime Keis"'
Number of results to display per page
Search Results
2. Publication Ethics in Biomedical Journals from Countries in Central and Eastern Europe.
- Author
-
Mindaugas Broga, Goran Mijaljica, Marcin Waligora, Aime Keis, and Ana Marusic
- Published
- 2014
- Full Text
- View/download PDF
3. The 1st year of the COVID-19 epidemic in Estonia: an interrupted time series of population based nationwide cross-sectional studies
- Author
-
Jaak Vilo, Uku Raudvere, Liis Kolberg, Ene Käärik, Hedi Peterson, Kristjan Vassil, Tuuli Jürgenson, Mait Metspalu, Ene-Margit Tiit, Ruth Kalda, Mihkel Solvak, Anneli Uusküla, Lili Milani, Meelis Käärik, Mikk Jürisson, Aime Keis, and Krista Fischer
- Subjects
Response rate (survey) ,Selection bias ,education.field_of_study ,business.industry ,Cross-sectional study ,media_common.quotation_subject ,Population ,Odds ,Vaccination ,Trend analysis ,Health care ,Medicine ,business ,education ,Demography ,media_common - Abstract
BackgroundDecisions about the continued need for control measures and the effect of introducing COVID-19 vaccinations rely on accurate and population-based data on SARS-CoV-2 positivity and risk factors for testing positive.MethodsIn this interrupted time series of population-based nationwide cross-sectional studies, data from nasopharyngeal testing and questionnaires were used to estimate the SARS-CoV-2 RNA prevalence and factors associated with test positivity over the 1st year of the COVID-19 epidemic.The study is registered with the ISRCTN Registry, ISRCTN10182320.ResultsBetween April 23, 2020 and February 2, 2021, results were available from 34,915 individuals and 27,870 samples from 11 consecutive studies. The percentage of people testing positive for SARS-CoV-2 decreased from 0.27% (95% CI 0.10% - 0.59%) in April to 0.04% (95% CI 0.00% - 0.22%) by the end of May and remained very low (0.01%, 95% CI 0.00% - 0.17%) until the end of August, followed by an increase since November (0.37%, 95% CI 0.18% - 0.68%) that escalated to 2.69% (95% CI 2.08% - 2.69%) in January 2021. In addition to substantial change in time, an increasing number of household members (for one additional OR 1.15, 95% CI 1.02-1.29), reporting current symptoms of COVID-19 (OR 2.21, 95% CI 1.59-3.09), and completing questionnaire in the Russian language (OR 1.85, 95% CI 1.15-2.99) were associated with increased odds for SARS-CoV-2 RNA positivity.ConclusionsSARS-CoV-2 population prevalence needs to be carefully monitored as vaccine programmes are rolled out in order to inform containment decisions.Strengths and limitations of this studyOur study relies upon nation-wide and population-based data on SARS-CoV-2 prevalence, and presents changes in prevalence over the whole 1st year of the Covid-19 epidemic.Our analysis of SARS-CoV-2 infection risk factors is not limited to notification or health care-based case data.Selection bias may have been introduced as a result of low response rate. The direction of bias is unclear, but most likely operates rather uniformly over the period of observation, though this presents less of a threat to the SARS-CoV-2 prevalence trend analysis.Our data could be used to adequately project the future course of the SARS-CoV-2 epidemic and the effect of control measures.
- Published
- 2021
4. Biobanking in Estonia
- Author
-
Aime Keis
- Subjects
Estonia ,medicine.medical_specialty ,Databases, Factual ,Population ,Legislation ,Public administration ,0603 philosophy, ethics and religion ,03 medical and health sciences ,0302 clinical medicine ,Political science ,Health care ,medicine ,Humans ,030212 general & internal medicine ,education ,Biological Specimen Banks ,education.field_of_study ,Government ,business.industry ,Health Policy ,Public health ,Parliamentary republic ,06 humanities and the arts ,General Medicine ,Biobank ,Estonian ,language.human_language ,Europe ,Issues, ethics and legal aspects ,language ,Public Health ,060301 applied ethics ,business - Abstract
Estonia is a democratic, parliamentary republic with a health care system that is built on the principle of compulsory, solidarity-based insurance and the all-round availability of services of private service providers. Estonia has specific biobank legislation as well as oversight via data protection laws. Its population-based biobank, the Estonian Genome Center (EGCUT), established in 2001, is one of the largest biobanks in Europe, and its database may be used only for scientific research, public health research, and statistics. The EGCUT can issue data to a third party, but only in coded form. This comprehensive database of genotypic, phenotypic, health, and genealogical information represents about 5% of Estonia's adult population, and is the largest cohort ever gathered in Estonia. Government approval is required for international data sharing, and sharing can be further limited by the requirement of ethics approval and permission from Estonian government.
- Published
- 2016
5. A meta-analysis of genome-wide association studies identifies novel variants associated with osteoarthritis of the hip
- Author
-
William E R Ollier, Gillian A. Wallis, Unnur Styrkarsdottir, Nicholas G. Martin, P. Eline Slagboom, Mike R. Reed, Helgi Jonsson, J. Mark Wilkinson, John P. A. Ioannidis, Aime Keis, Yolande F. M. Ramos, Daniel S. Evans, Penelope A. Lind, Stuart H. Ralston, Thorvaldur Ingvarsson, Andrew McCaskie, Konstantinos K. Tsilidis, Evangelos Evangelou, Kay Chapman, Tim D. Spector, Aaron G. Day-Williams, L. Stefan Lohmander, Aspasia Tsezou, Ashok Rai, Rob G H H Nelissen, Kari Stefansson, Cristina Rodriguez-Fontenla, Sarah Metrustry, Andres Metspalu, Kalliope Panoutsopoulou, Albert Hofman, Hanneke J. M. Kerkhof, John Loughlin, Panos Deloukas, Joyce B. J. van Meurs, Ana M. Valdes, Evangelia E. Ntzani, Lorraine Southam, José A. Riancho, J. Christiaan Keurentjes, Francisco J. Blanco, Gudmar Thorleifsson, Peter M. Nilsson, Ingrid Meulenbelt, Lili Milani, Fernando Rivadeneira, Michael C. Nevitt, Nicholas Bellamy, Nancy E Lane, Unnur Thorsteinsdottir, Grant W. Montgomery, Michael Doherty, Tõnu Esko, Ingileif Jonsdottir, Nigel K Arden, Hafdis T. Helgadottir, André G. Uitterlinden, Antonio Gonzalez, Steffan D. Bos, Margreet Kloppenburg, Andrew Carr, Eleftheria Zeggini, Gunnar Engström, N Aslam, Fraser Birrell, Neeta Parimi, Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece Department of Twin Research & Genetic Epidemiology, King's College London, London, UK. 2Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. 3Department of Population Genetics, deCODE Genetics, Reykjavik, Iceland. 4Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece. 5Department of Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands Netherlands Consortium for Healthy Ageing, The Netherlands. 6Estonian Genome Center, University of Tartu, Tartu, Estonia Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia. 7California Pacific Medical Center Research Institute, San Francisco, USA. 8Department of Twin Research & Genetic Epidemiology, King's College London, London, UK. 9Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton, UK. 10Department of Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands. 11NIHR Biomedical Research Unit and ARUK Centre of excellence for Sport, Exercise and Osteoarthritis, University of Oxford, Oxford, UK MRC Epidemiology Resource Centre, University of Southampton, Southampton, UK. 12Worcestershire Royal Hospital, Worcestershire Acute Hospitals NHS Trust, Worcester, UK. 13Centre of National Research on Disability and Rehabilitation Medicine, The University of Queensland, Brisbane, Australia. 14Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK Wansbeck General Hospital, Northumbria Healthcare NHS Foundation Trust, Ashington, UK. 15Rheumatology Division, Instituto de Investigación Biomédica-Hospital Universitario A Coruña, A Corunna, Spain. 16NIHR Biomedical Research Unit and ARUK Centre of excellence for Sport, Exercise and Osteoarthritis, University of Oxford, Oxford, UK. 17Department of Academic Rheumatology, University of Nottingham, Nottingham, UK. 18Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden. 19Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands. 20Department of Orthopedic Surgery, Akureyri Hospital, Akureyri, Iceland School of Health Sciences, University of Akureyri, Akureyri, Iceland. 21Department of Medicine, The National University Hospital of Iceland, Reykjavik, Iceland Faculty of Medicine, University of Iceland, Reykjavik, Iceland. 22Department of Public Health, University of Tartu, Tartu, Estonia Orthopedic Surgeons, Elva Hospital, Elva, Estonia. 23Department of Orthopedics, Leiden University Medical Center, Leiden, The Netherlands. 24Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. 25Department of Quantitative Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia. 26Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. 27Department of Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Australia. 28Estonian Genome Center, University of Tartu, Tartu, Estonia. 29Department of Molecular Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Australia. 30Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA. 31Centre for Integrated Genomic Medical Research, University of Manchester, Manchester, UK. 32Worcestershire Acute Hospitals NHS Trust, Worcester, UK. 33Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. 34Wansbeck General Hospital, Northumbria Healthcare NHS Foundation Trust, Ashington, UK. 35Department of Internal Medicine, Hospital U.M. Valdecilla-IFIMAV, University of Cantabria, Santander, Spain. 36Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands. 37Laboratorio Investigacion 10 and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain. 38Department of Population Genetics, deCODE Genetics, Reykjavik, Iceland Department of Medicine, The National University Hospital of Iceland, Reykjavik, Iceland. 39Department of Biology, University of Thessaly, Medical School, Larissa, Greece. 40Wellcome Trust Centre for Cell-Matrix Research, University of Manchester, Manchester, UK. 41Department of Human Metabolism, University of Sheffield, Sheffield, UK. 42Department of Medicine, University of California at Davis, Sacramento, USA. 43Research Unit for Musculoskeletal Function and Physiotherapy, and Department of Orthopedics and Traumatology, University of Southern Denmark, Odense, Denmark Department of Clinical Sciences Lund, Lund University, Lund, Sweden. 44Department of Population Genetics, deCODE Genetics, Reykjavik, Iceland Faculty of Medicine, University of Iceland, Reykjavik, Iceland. 45Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, USA. 46Department of Twin Research & Genetic Epidemiology, King's College London, London, UK Department of Academic Rheumatology, University of Nottingham, Nottingham, UK., arcOGEN Consortium, Universidad de Cantabria, Medical Oncology, Epidemiology, and Internal Medicine
- Subjects
Male ,Aging ,Epidemiology ,Genome-wide association study ,Calcium-Calmodulin-Dependent Protein Kinase Type 2/genetics ,Bioinformatics ,Osteoarthritis, Hip ,Nuclear Receptor Coactivator 3 ,Gene Frequency ,Grupo de Ascendencia Continental Europea ,Immunology and Allergy ,Medicine ,2.1 Biological and endogenous factors ,Osteoarthritis, Hip/genetics ,Aetiology ,European Continental Ancestry Group/genetics ,Gene polymorphism ,Single Nucleotide ,Protein-Tyrosine Kinases ,Protein-Serine-Threonine Kinases ,3. Good health ,Slitgigt ,1117 Public Health And Health Services ,1107 Immunology ,Nuclear Receptor Coactivator 3/genetics ,Female ,arcOGEN Consortium ,Frecuencia de los Genes ,Protein-Serine-Threonine Kinases/genetics ,Clinical Sciences ,Immunology ,European Continental Ancestry Group ,Predisposición Genética a la Enfermedad ,Single-nucleotide polymorphism ,Locus (genetics) ,Protein Serine-Threonine Kinases ,Public Health And Health Services ,Polymorphism, Single Nucleotide ,General Biochemistry, Genetics and Molecular Biology ,Immediate early protein ,White People ,Proteína Quinasa Tipo 2 Dependiente de Calcio Calmodulina ,Estudio de Asociación del Genoma Completo ,Immediate-Early Proteins ,Sex Factors ,Rheumatology ,Gene Polymorphism ,Osteoarthritis ,Genetics ,Humans ,Genetic Predisposition to Disease ,Polymorphism ,Allele frequency ,Genetic association ,Rheumatology and Autoimmunity ,Homeodomain Proteins ,Hip ,Protein-Tyrosine Kinases/genetics ,business.industry ,Whites ,Arthritis ,Prevention ,Human Genome ,1103 Clinical Sciences ,Clinical and Epidemiological Research ,Arfgengi ,Immediate-Early Proteins/genetics ,Arthritis & Rheumatology ,Minor allele frequency ,Musculoskeletal ,Mjaðmir ,HMGN Proteins ,Osteoartritis de la Cadera ,Homeodomain Proteins/genetics ,business ,Calcium-Calmodulin-Dependent Protein Kinase Type 2 ,HMGN Proteins/genetics ,Genome-Wide Association Study - Abstract
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files. This article is open access. Osteoarthritis (OA) is the most common form of arthritis with a clear genetic component. To identify novel loci associated with hip OA we performed a meta-analysis of genome-wide association studies (GWAS) on European subjects. We performed a two-stage meta-analysis on more than 78,000 participants. In stage 1, we synthesised data from eight GWAS whereas data from 10 centres were used for 'in silico' or 'de novo' replication. Besides the main analysis, a stratified by sex analysis was performed to detect possible sex-specific signals. Meta-analysis was performed using inverse-variance fixed effects models. A random effects approach was also used. We accumulated 11,277 cases of radiographic and symptomatic hip OA. We prioritised eight single nucleotide polymorphism (SNPs) for follow-up in the discovery stage (4349 OA cases); five from the combined analysis, two male specific and one female specific. One locus, at 20q13, represented by rs6094710 (minor allele frequency (MAF) 4%) near the NCOA3 (nuclear receptor coactivator 3) gene, reached genome-wide significance level with p=7.9×10(-9) and OR=1.28 (95% CI 1.18 to 1.39) in the combined analysis of discovery (p=5.6×10(-8)) and follow-up studies (p=7.3×10(-4)). We showed that this gene is expressed in articular cartilage and its expression was significantly reduced in OA-affected cartilage. Moreover, two loci remained suggestive associated; rs5009270 at 7q31 (MAF 30%, p=9.9×10(-7), OR=1.10) and rs3757837 at 7p13 (MAF 6%, p=2.2×10(-6), OR=1.27 in male specific analysis). Novel genetic loci for hip OA were found in this meta-analysis of GWAS. info:eu-repo/grantAgreement/EC/FP7/200800 info:eu-repo/grantAgreement/EC/FP7/286213
- Published
- 2014
6. A Variant in MCF2L Is Associated with Osteoarthritis
- Author
-
Weiya Zhang, Unnur Styrkarsdottir, Andrew McCaskie, Stuart H. Ralston, Ollier Wer., Karol Estrada, Sally Doherty, Nigel W. Rayner, Kerkhof Hjm., Kay Chapman, I Carluke, Andrew Carr, Gillian A. Wallis, Gudmar Thorleifsson, John Loughlin, Rose A. Maciewicz, Tim D. Spector, F Birell, Michael Doherty, Eleftheria Zeggini, J Joseph, Mike R. Reed, Fernando Rivadeneira, N Aslam, van Meurs Jbj., Ashok Rai, A.G. Uitterlinden, Panagiotis Deloukas, Kalliope Panoutsopoulou, K Walker, Albert Hofman, Lorraine Southam, Aime Keis, Thorvaldur Ingvarsson, Kenneth Muir, Jeremy Mark Wilkinson, Kari Stefansson, Tõnu Esko, Ingileif Jonsdottir, Hakon Jonsson, Aaron G. Day-Williams, Ana M. Valdes, Andres Metspalu, Nigel K Arden, Hafdis T. Helgadottir, Epidemiology, and Internal Medicine
- Subjects
Oncology ,medicine.medical_specialty ,Locus (genetics) ,Single-nucleotide polymorphism ,Genome-wide association study ,Osteoarthritis ,Biology ,Bioinformatics ,Polymorphism, Single Nucleotide ,White People ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,MISSING HERITABILITY ,Internal medicine ,Report ,Nerve Growth Factor ,medicine ,Odds Ratio ,IMPUTATION ,Genetics ,Guanine Nucleotide Exchange Factors ,Humans ,Genetic Predisposition to Disease ,Genetics(clinical) ,GENOME-WIDE ASSOCIATION ,Genetics (clinical) ,METAANALYSIS ,030304 developmental biology ,Chromosome 13 ,030203 arthritis & rheumatology ,0303 health sciences ,Chromosomes, Human, Pair 13 ,GDF5 ,Antibodies, Monoclonal ,PAIN ,Odds ratio ,medicine.disease ,GENOTYPES ,Confidence interval ,3. Good health ,Meta-analysis ,KNEE ,PROJECT ,Rho Guanine Nucleotide Exchange Factors ,Genome-Wide Association Study - Abstract
Osteoarthritis (OA) is a prevalent, heritable degenerative joint disease with a substantial public health impact. We used a 1000-Genomes-Project-based imputation in a genome-wide association scan for osteoarthritis (3177 OA cases and 4894 controls) to detect a previously unidentified risk locus. We discovered a small disease-associated set of variants on chromosome 13. Through large-scale replication, we establish a robust association with SNPs in MCF2L (rs11842874, combined odds ratio [95% confidence interval] 1.17 [1.11-1.23], p = 2.1 x 10(-8)) across a total of 19,041 OA cases and 24,504 controls of European descent. This risk locus represents the third established signal for OA overall. MCF2L regulates a nerve growth factor (NGF), and treatment with a humanized monoclonal antibody against NGF is associated with reduction in pain and improvement in function for knee OA patients.
- Published
- 2011
- Full Text
- View/download PDF
7. The Estonian Genome Center, University of Tartu
- Author
-
Aime Keis
- Subjects
Supervisory board ,Political science ,language ,Library science ,Center (algebra and category theory) ,Genome ,Estonian ,Genealogy ,language.human_language - Abstract
The Estonian Genome Center, University of Tartu (EGCUT) was incorporated as a research and development institution at the University of Tartu, Estonia, on the first of April 2007.
- Published
- 2015
8. Publication Ethics in Biomedical Journals from Countries in Central and Eastern Europe
- Author
-
Marcin Waligóra, Mindaugas Broga, Goran Mijaljica, Aime Keis, Ana Marušić, Department of Ethical Didactics, Lithuanian University of Educational Sciences, Psychiatric Hospital Ugljan, Zadar, Croatia, University of Split School of Medicine, Split, Croatia, Department of Philosophy and Bioethics, Medical College, Jagiellonian University, Krakow, Poland, Department of Public Health, University of Tartu, Tartu, Estonia, and Department of Research in Biomedicine and Health, University of Split School of Medicine, Split, Croatia
- Subjects
Biomedical Research ,Health (social science) ,Publication ethics ,Ethical criteria ,Central and Eastern Europe ,Research ethics ,MEDLINE ,Public administration ,0603 philosophy, ethics and religion ,Health(social science) ,Ethics, Research ,03 medical and health sciences ,0302 clinical medicine ,Copyright ,Management of Technology and Innovation ,Political science ,Humans ,media_common.cataloged_instance ,Europe, Eastern ,European Union ,030212 general & internal medicine ,European union ,media_common ,Publishing ,Original Paper ,Philosophy of science ,Conflict of Interest ,business.industry ,Health Policy ,Conflict of interest ,06 humanities and the arts ,Public relations ,3. Good health ,Issues, ethics and legal aspects ,060301 applied ethics ,Periodicals as Topic ,business ,Editorial Policies - Abstract
Publication ethics is an important aspect of both the research and publication enterprises. It is particularly important in the field of biomedical science because published data may directly affect human health. In this article, we examine publication ethics policies in biomedical journals published in Central and Eastern Europe. We were interested in possible differences between East European countries that are members of the European Union (Eastern EU) and South-East European countries (South-East Europe) that are not members of the European Union. The most common ethical issues addressed by all journals in the region were redundant publication, peer review process, and copyright or licensing details. Image manipulation, editors’ conflicts of interest and registration of clinical trials were the least common ethical policies. Three aspects were significantly more common in journals published outside the EU: statements on the endorsement of international editorial standards, contributorship policy, and image manipulation. On the other hand, copyright or licensing information were more prevalent in journals published in the Eastern EU. The existence of significant differences among biomedical journals’ ethical policies calls for further research and active measures to harmonize policies across journals. US National Institutes of Health (NIH) Fogarty International Center,R25 TW007085; National Science Center (NCN) Poland, DEC-2011/03/D/HS1/01695 Marcin Waligóra
- Published
- 2014
9. Biobanking in Estonia.
- Author
-
Keis A
- Subjects
- Databases, Factual, Estonia, Europe, Humans, Biological Specimen Banks, Public Health
- Abstract
Estonia is a democratic, parliamentary republic with a health care system that is built on the principle of compulsory, solidarity-based insurance and the all-round availability of services of private service providers. Estonia has specific biobank legislation as well as oversight via data protection laws. Its population-based biobank, the Estonian Genome Center (EGCUT), established in 2001, is one of the largest biobanks in Europe, and its database may be used only for scientific research, public health research, and statistics. The EGCUT can issue data to a third party, but only in coded form. This comprehensive database of genotypic, phenotypic, health, and genealogical information represents about 5% of Estonia's adult population, and is the largest cohort ever gathered in Estonia. Government approval is required for international data sharing, and sharing can be further limited by the requirement of ethics approval and permission from Estonian government., (© 2016 American Society of Law, Medicine & Ethics.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.